

Humber Area Prescribing Committee

Date / Time	5 th July 2023 13:00-15:00
Venue	MS Teams
Chair	Dr Sergio Raise
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, HUTH
Quorate: Yes / No	No – JM to send papers to Joanne Goode (items ratified after meeting)

Attendance	Dr Sergio Raise, ERY GP Prescribing Lead (SR) Luke Storr – Senior Pharmacy Technician, HUTH (LS) Prof A Morice, Professor of Respiratory Medicine HUTH- (AM) Daniel Newsome- Principal Pharmacist RDTC (DN) Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc) Rachel Staniforth, Medicines Optimisation Pharmacist, NECS (RS) Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Dr Rolan Schreiber, Professional Secretary LMC (RSc) Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK) Dr Anupam Sinha- NEL GP Prescribing Lead (AS) Marian Opoku-Fofie – Deputy Chief Pharmacist – Humber Teaching NHS Foundation Trust (MOF) Narayana Pothina- Consultant in adult medicine, NLAG (NP) Emma Baggaley, Assistant Director Medicines Management (Superintendent Pharmacist), CHCP (EB) Simon Priestley- Chief Pharmacist, NLAG (SP) Dr Patik Basu- NL GP, The Birches medical practice (PB) Peter Louth- Nurse HUTH (PL) Lesley Harrison- HUTH (LH) Manjeet Kaur-Deputy Chief Pharmacist, RDASH (MK)
-------------------	---

Apologies	Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM) Joanne Goode – Chief Pharmacist – HUTH (JG)
------------------	--

Agenda Number	Item	Discussion	Action	Lead	Due Date
2023.07.01	Apologies	Noted above			
2023.07.02	Declarations of interest	None			
2023.07.03	Minutes of previous meeting	Accepted as true record			
2023.07.04	Action Tracker	<p>Prescription requests in primary care –action transferred from NLAPC to Humber APC To produce joint document detailing supply details from secondary to primary care for all providers within Humber region To add links to relevant HUTH and NLAG guidance to website for information for primary care (discharge policies) June 2023: In progress July 2023: In progress</p> <p>Ratification of guidelines and SCFs Add type 2 diabetes guidelines as recommendation for discussion at IMOC (action complete) NEW actions To feedback IMOC recommendation to clinicians To feedback to APC when meeting between all services occurred December update – going around internal governances in trusts (HUTH/NLAG/Y&SFT/HDH) March update – still awaiting outcome from relevant governances, JM to discuss with Matthew Heppel May update-sent to RS, to review how to do costing June update- JM discussed with Matthew Heppel and most urgent issue to resolve is step 1 of NICE guidance. Proposed to send the North Yorkshire APC approved guidance as Humber guidance to July guideline group. Then</p>	<p>Ongoing</p> <p>Ongoing</p>	<p>AK/JM</p> <p>JM</p>	<p>8/23</p> <p>8/23</p>

		<p>can work on the more complex local commissioning of other agents. July 2023 – on agenda for guideline group</p> <p>Action tracker HERPC – Hydroxychloroquine SCF JM to prepare hydroxychloroquine SCF</p> <p>Outstanding actions from NLAPC Funding for SCFs – mycophenolate, modafinil and riluzole (joint SCFs) December update: JM provided RS with patient numbers for mycophenolate, modafinil and riluzole Feb update- Modafinil live in NEL Riluzole live in NEL March update: SCFs uploaded onto Humber APC and linked into formulary. Awaiting NL – RS to update May update: Riluzole updated, modafinil still waiting for NL,mycophenolate to review June update: Modafinil still waiting on NL, JM to review mycophenolate for July guideline group July update: JM to review mycophenolate SCF and update on new template for July guideline group or September guideline group dependant on agenda size. JM to correct typing error and send updated version to RS</p> <p>Outstanding actions from NLAPC Funding for SCF – Azathioprine/6MP (NEL/N) AK to provide RS information on number of patients in NEL/NL Feb update Azathioprine live in NEL March update: SCF uploaded onto website, awaiting NL – RS to update May update: AK to check netformulary and Humber APC site June update: AK to update netformulary and Humber APC site (remove duplicate SCF) July update: AK to removed duplicate SCF</p> <p>Outstanding actions from HERPC Renal repatriation: December update – JM to meet with renal Dec update – JM offered dates of meeting but no correspondence March update – Updating business case. May update- to meet with NHSE</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p> <p>Ongoing</p>	<p>JM</p> <p>JM/RS</p> <p>AK</p> <p>JM</p>	<p>6/23</p> <p>8/23</p> <p>8/23</p> <p>8/23</p>
--	--	--	---	--	---

		<p>July update – JM not present to update, to update next time</p> <p>Ratification of joint formulary To upload chapter 13 on netformulary and remove HERPC chapter March update – still ongoing May update- still ongoing June update – still ongoing July update – net formulary almost complete, need final check and then delete HERPC chapter</p> <p>Ratification of joint formulary To add chapter 1 to netformulary (and remove HERPC chapter when complete) July update – JM/LS/AK to start adding when chapter 13 complete</p> <p>Blueteq compliance Non-compliance to NICE guidance in acute trusts and financial impact June update: JM to submit ustekinumab report in gastroenterology HUTH when approved JM to present infliximab maintenance and initiation audits in gastroenterology HUTH when completed and approved July update: JM started infliximab maintenance data collection and requesting data for adalimumab in gastroenterology homecare. Ustekinumab audit report not ready yet.</p> <p>Traffic Light Status To update formulary and red list</p> <p>Ratification of guidelines and SCFs To add to website after updates and approval from required (SP/NP) members not in attendance</p> <p>Ratification of guidelines and SCFs Infliximab in ASUC – to add additional information and re-present when updated July update: discussed under Blueteq above, JM to bring updated paper in August/September</p> <p>RTDC updates To update formulary with TAs which were approved</p> <p>Correspondence received</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p> <p>Ongoing</p> <p>Action complete</p>	<p>JM/AK/LS</p> <p>AK/LS/JM</p> <p>JM</p> <p>LS/AK</p> <p>JM</p> <p>JM</p> <p>AK/LS</p> <p>JM</p>	<p>8/23</p> <p>9/23</p> <p>9/23</p> <p>7/23</p> <p>7/23</p> <p>8/23</p> <p>7/23</p> <p>7/23</p>
--	--	---	--	---	---

		To feedback discussion regarding ondansetron to Paulash Haider at NLAG	Action complete		
2023.07.05	Outstanding actions from HERPC	<ul style="list-style-type: none"> Correspondence Received Rheumatology to prepare pathway with rituximab without MTX August update – JM to contact Dr Ogumbambi for timeline October update – JM to contact Dr Ogumbambi again November update – Arranging meeting to discuss guidance and timeframe December update – Meeting booked February update – Documents sent to Dr Ogumbambi – March update – JM chased Dr Ogumbambi as received NLAG documents April update – JM to chase Dr Ogumbambi again May update – To discuss at HUTH D&Tc and add to D&TC action tracker June update – Discussed at HUTH D&TC and added to D&TC action tracker Hydroxychloroquine SCF JM to discuss ophthalmology checks with rheumatology New action: JM to add Harrogate pathway to agenda when published. New Action: JM to meet with business manager in ophthalmology to discuss drafting HUTH pathway and work towards commissioning. September 2022 update – HUTH D&T are escalating internally via their escalation process. To prepare SCG (action for HAPC) October 2022 – HUTH D&TC haven't had reply from their escalation process (JM chasing) November 2022 – HUTH D&TC haven't had reply from their escalation process December 2022 – HUTH meeting later this month. February 2023 – To check PE&CE minutes March 2023 – To discuss PE&CE response at next D&TC April 2023 – To discuss at next HUTH D&TC May 2023 – re-escalated from HUTH D&TC June 2023- JM going to PE&CE Prescribing guidelines – Dienogest pathway JM to confirm prescribing arrangements with specialist team October update: JM contacted Mrs Allen who is service lead, noted not stocked in HUTH pharmacy, thus stock 	Added to HUTH D&T agenda	JM	9/22
			Ongoing	JM	4/23
			Ongoing	JM	7/23

		<p>arranged in pharmacy. No response from e-mail to consultant but specialist nurse responded.</p> <p>November update – JM to check formularies and EMIS dispensing system.</p> <p>December update – JM to chase consultant</p> <p>February update – JM met consultant and going to update pathway</p> <p>March update –JM to update pathway</p> <p>May update – JM not updated pathway yet</p> <p>June update – Pathway for July guideline group (dependant on agenda size)</p>			
2023.07.06	Traffic Light Status	<p>Teduglutide- Proposed as RED</p> <p>Ibuprofen IV- Proposed as RED, additional work on adult dosing</p> <p>Tenecteplase- Proposed as RED</p> <p>Tranexamic acid mouthwash- Proposed as RED</p> <p>Duraphat toothpaste- Proposed as RED</p> <p>Vagirax- Proposed as GREEN</p> <p>Ketamine- Proposed as RED</p> <p>Capsaicin Cream 0.075%- Proposed as GREEN</p> <p>Procainamide- Remove from formulary</p>	Update formulary/red list	LS/AK	8/23
2023.07.07	Feedback from Integrated Medicines Optimisation Committee	June meeting cancelled	Noted		
2023.07.08	Work plans	<p>a) Joint formulary alignment</p> <p>b) Shared care frameworks</p> <p>c) Guidelines</p>	Ongoing for information only		
2023.07.09	Ratification of guidelines and SCFs	Nil this month			
2023.07.10	Ratification of joint formulary	Nil this month			
2023.07.11	RTDC updates	<ul style="list-style-type: none"> May 23- to update formulary 	Update formulary/red list	JM/LS/AK	8/23
2023.07.12	Minutes from subcommittees	<p>a) Joint formulary subcommittee (April 2023)</p> <p>b) Guideline subcommittee (Nil)</p>	Attached for info only		
2023.06.13	Additional minutes for information	<p>a) HUTH D&TC (May 2023)</p> <p>b) HFT DTG (Nil)</p> <p>c) NLAG M&T (Nil)</p> <p>d) NYY APC (Nil)</p>	Attached for info only		
2023.06.15	Correspondence received	Inclisiran- Amber 1 at present. Request for Amber 2/Green will revisit at Guideline group/joint formulary	Add to agenda	LS	8/23

2023.06.16	AOB	Children's Ondansetron- Pathway to be sent to NLAG M&T and primary secondary care interface meeting Ozempic- Discussions over use within primary care. Suggestion of changing to RED and note not for weight management. To ensure netFormulary states product not available by TA.			
2023.06.17	Date of next meeting	2 nd August 13.00 – 15.00 Teams			